Safety & evidence

Do peptides
work?

The honest answer depends on which peptide you mean and what you want it to do. Here is where the evidence is strong, where it stops, and why a photo pair or a testimonial cannot fill the gap.

Short answerSafety & evidence · 7 min read · Updated 21 Nov 2026

It depends on which peptide, and on what “work” means. An approved peptide medicine has had its safety and effectiveness reviewed by a regulator, for the uses on its label only. For BPC-157, a 2025 systematic review of musculoskeletal research found 35 of its 36 studies were preclinical. Photos and testimonials cannot settle the question.

Key takeaways

  • “Peptide” names a kind of molecule, so the question has to be asked one compound and one use at a time.
  • FDA says people rely on its approval process to verify a medicine’s safety, effectiveness and quality; an approval covers the uses on that product’s label.
  • BPC-157: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical, and we found no peer-reviewed randomised trial in people (PubMed, 21 November 2026).
  • A photo pair has no comparison group, and pose alone can change how a face looks in a picture: a 2004 study showed this with 20 judges and three subjects.
  • The US Federal Trade Commission’s endorsement guides state: “Consumer endorsements themselves are not competent and reliable scientific evidence.”

01Do peptides work?

It depends on which peptide, and on what “work” means. “Peptide” names a kind of molecule, not a product. The word covers approved medicines, cosmetic ingredients and unapproved research compounds, and the evidence behind them differs widely.

One research compound shows the gap. This is how far the published research on BPC-157 has gone.

Cell studies
Extensive
Animal studies
Extensive
Human pilot / case series
Minimal
Controlled human trials
Abstracts only
Regulatory approval
None

A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical; the one human study had no control group.

Source: Vasireddi et al., HSS J, 2025; FDA briefing document, July 2026

For an approved medicine, a regulator has reviewed the human trials behind each use on the label. For BPC-157, we found no peer-reviewed randomised trial in people (PubMed, 21 November 2026). More: the BPC-157 guide.

02How do peptides work?

Many of the body’s own peptides are messengers. A peptide hormone is released, travels in the blood, and binds a receptor on the surface of a target cell. The receptor then starts a signalling pathway inside the cell. Water-soluble hormones cannot pass through the cell membrane, so they act from outside it. The full sequence is on how peptides work in the body.

That is a mechanism, and a mechanism is a starting point. A compound that binds a receptor in a dish, or changes a measure in a rat, has shown what it can do in that model. Whether it does the same in a person has to be tested in people. Animal results do not always carry over: a 2007 systematic review found treatments that helped in animal models but showed no benefit, or worse outcomes, in patients.

How we rank study designs: evidence grades.

03What kind of evidence stands behind each kind of peptide?

Three examples, one of each kind. The steps run from cell studies up to randomised trials in people. The marker shows the highest step reached; the flag is a regulator’s approval.

Approved medicine

Semaglutide

Wegovy is a prescription medicine. STEP 1 (2021), one trial behind it, randomised 1,961 adults without diabetes to semaglutide or placebo for 68 weeks. Research-grade material sold under the name is not this medicine.

Cosmetic ingredient

Palmitoyl pentapeptide

A randomised, split-face trial run at Procter & Gamble (2005): 93 women, 12 weeks, wrinkles and fine lines measured in facial images. Cosmetic ingredients do not require FDA approval before sale.

Research compound

BPC-157

Mostly cell and animal studies. In people, the only randomised, placebo-controlled data are conference abstracts from 2002 to 2005.

04What is the strongest evidence for each kind, and what has not been shown?

One row per example. “Strongest evidence” means the most rigorous study design we found, not the most favourable finding (checked 21 November 2026).

Kind of peptide (example)Strongest evidence that existsWhat has not been shown
Approved medicine (semaglutide, as Wegovy; prescription only)Randomised, double-blind, placebo-controlled trials, reviewed by FDA. STEP 1: 1,961 adults with obesity, or overweight plus a weight-related condition, and no diabetes; 68 weeks; change in body weight as the main measure; funded by the maker.Anything outside the label. The label’s boxed warning says semaglutide causes thyroid C-cell tumours in rodents and “It is unknown whether WEGOVY causes thyroid C-cell tumors” in humans. Research-grade material sold under the name is not this medicine.
Cosmetic peptide in a cream (palmitoyl pentapeptide)A randomised, double-blind, split-face trial: 93 women aged 35 to 55, 12 weeks, wrinkles and fine lines measured in facial images (2005). Run at a company that sells skin-care products.Anything beyond appearance: FDA says a product intended to affect the structure or any function of the body is a drug.
Research compound with small human studies (BPC-157)Mostly animal and cell studies: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical. Randomised, placebo-controlled data exist only as conference abstracts (2002 to 2005). A randomised phase 2 trial is recruiting (120 planned).An effect in people in a peer-reviewed randomised trial. A safety profile: FDA staff found “insufficient clinical safety information to characterize the safety profile”.
Research compounds not given to people in a controlled study (MOTS-c, TB-500)MOTS-c: mouse and cell studies; FDA staff “did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans”. TB-500: animal and cell studies; FDA staff found no article in which it was given to humans, and a later 2026 report describes three patients given it with other agents, without a control group.Any effect in people. FDA staff: potential safety risks of TB-500 in humans “are unknown”. A randomised trial of each is registered and recruiting, with nothing posted yet.
Mixes of three or four peptides in one vialNone for the mix. We found no published study, in any species, that tested a mix of GHK-Cu, BPC-157 and TB-500, with or without KPV (PubMed, 21 November 2026). ClinicalTrials.gov lists no trial that tests two or more of them together.Everything about the mix. Evidence attaches to the compound studied, on its own. More: peptide blends.

The same grading, compound by compound, is on peptides graded by evidence.

05Why are photos and testimonials weak evidence?

If you searched for “peptides before and after”, this section is the answer. A pair of photos, or a story from someone who used a product, feels like proof. Six reasons why neither can show that a compound did anything.

No comparison group.

A photo pair shows one person at two moments. Without a similar group that did not get the compound, nothing separates its effect from everything else. A 2018 review of this kind of comparison names eleven sources of bias, and lists a control group first among the fixes.

Pose and editing.

In a 2004 study, 20 judges rated photos of three people in different head and neck positions. Small changes in position altered how the jawline and the area under the chin looked. In 2026, an automated detector flagged probable digital edits in 117 of 600 public surgery photos on one platform.

Other things changed too.

Between two photos, training, diet, sleep, other treatments and time itself may all have changed. Study designers call these history and maturation effects. A single photo pair cannot separate them from the compound.

Extremes drift back.

Unusually large or small measurements tend to be followed by ones closer to the average. A 2005 paper describes this as a statistical effect that “can make natural variation in repeated data look like real change”.

You see the chosen ones.

The photos and stories that get posted are the ones someone chose to post. The US Federal Trade Commission’s endorsement guides say a testimonial in an ad will likely be read as typical of what consumers generally achieve, and that the advertiser should hold proof that it is.

Placebo and biased reporting.

A Cochrane review with data from 202 trials found no important clinical effects of placebo interventions in general, but concluded that in certain settings they “can influence patient-reported outcomes, especially pain and nausea”, and that such effects are hard to tell apart from biased reporting. A 2026 review of peptides in sports medicine discusses the placebo effect, and how social media amplifies it.

The US Federal Trade Commission’s endorsement guides say it in one sentence: “Consumer endorsements themselves are not competent and reliable scientific evidence.” We publish no photo pairs and no user stories, for any compound.

The same limits apply to a clinic’s gallery and a seller’s reviews, and they cut both ways: a photo with no visible change does not show that a compound does nothing.

06What we don’t know

  • Whether findings from animal and cell studies of BPC-157, TB-500 or MOTS-c carry over to people. We found no peer-reviewed randomised trial that gave any of the three to people (PubMed, 21 November 2026).
  • What the registered trials will show. A randomised trial of each of the three is recruiting. A registration is a plan, not a finding.
  • How far a posted photo or story reflects the usual experience. The ones that were never posted are not collected anywhere we can check.
  • What was in the vial behind any story. Only a lab test of that sample can say.

Why we publish no amounts or schedules for any compound: why we don’t publish doses. How the prescription route is regulated: what is peptide therapy?

New studies and rule changes, once a week: the 6:00 brief.

Educational content, checked on 21 Nov 2026. Not medical advice. For anything about your health, a doctor who knows you is the right call.

RefSources

  1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025;21(4):485–495. PMID 40756949 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/40756949/
  2. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157-related bulk drug substances (PDF pp. 24, 27, 43). Advisory committee briefing, memo dated 11 May 2026; read 21 Nov 2026. www.fda.gov/media/193343/download
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: TB-500-related bulk drug substances (PDF pp. 21, 31). Advisory committee briefing, memo dated 15 May 2026; read 21 Nov 2026. www.fda.gov/media/193349/download
  4. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: MOTS-c-related bulk drug substances (PDF p. 31). Advisory committee briefing, memo dated 11 May 2026; read 21 Nov 2026. www.fda.gov/media/193347/download
  5. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. [Randomised, double-blind, placebo-controlled trial of semaglutide in 1,961 adults with overweight or obesity (STEP 1).] N Engl J Med, 2021;384(11):989–1002. PMID 33567185 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/33567185/
  6. Novo Nordisk. Wegovy (semaglutide) US prescribing information: boxed warning and section 1. DailyMed label, effective 18 Jun 2026; read 21 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2a…
  7. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (on what FDA’s approval process verifies). FDA page, content current as of 16 Sep 2025; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/compounding-and-fda…
  8. Robinson LR, Fitzgerald NC, Doughty DG, et al. [Split-face trial of a moisturiser with and without palmitoyl pentapeptide (pal-KTTKS) in 93 women.] Int J Cosmet Sci, 2005;27(3):155–160. PMID 18492182 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/18492182/
  9. U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). FDA page, content current as of 11 Sep 2024; read 21 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  10. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several agents, including BPC-157 and TB-500.] Front Oral Health, 2026;7:1907109. PMID 42876687 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/42876687/
  11. ClinicalTrials.gov records NCT07437547 (BPC-157, phase 2, randomised, recruiting, 120 planned), NCT07487363 (TB-500, phase 1/2, randomised, recruiting) and NCT07505745 (MOTS-c, phase 2, randomised, recruiting); none has posted data. Searches by intervention for BPC-157, TB-500, MOTS-c, KPV and GHK-Cu found no record testing two or more together. Registry API v2, read 21 Nov 2026. clinicaltrials.gov/study/NCT07437547
  12. PubMed searches for clinical-trial records of BPC-157, TB-500, MOTS-c and KPV, and for studies of mixes of GHK-Cu, BPC-157, TB-500 and KPV (queries in the claims list). Run 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28%22BPC-157%22%5Btiab%5D+OR+…
  13. Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e, section 17.2: Hormones. OpenStax (Rice University) textbook, 2022; read 21 Nov 2026. openstax.org/books/anatomy-and-physiology-2e/pages/17-2-horm…
  14. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ, 2007;334(7586):197. PMID 17175568 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/17175568/
  15. Ho AMH, Phelan R, Mizubuti GB, et al. [Narrative overview of bias in studies that compare one group at two time points without a concurrent control group.] Anesth Analg, 2018;126(5):1755–1762. PMID 29239959 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/29239959/
  16. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol, 2005;34(1):215–220. PMID 15333621 (abstract read 21 Nov 2026); correction Int J Epidemiol, 2015;44(5):1748, PMID 26270438. pubmed.ncbi.nlm.nih.gov/15333621/
  17. Sommer DD, Mendelsohn M. Pitfalls of nonstandardized photography in facial plastic surgery patients. Plast Reconstr Surg, 2004;114(1):10–14. PMID 15220560 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/15220560/
  18. Olabiran A, Kim R, Rohrich RJ. Detecting Manipulated Online Rhinoplasty Images Using an Artificial Intelligence Facial Authenticity Localization (FAL) Model. Plast Reconstr Surg, 2026 (online ahead of print). PMID 42765934 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/42765934/
  19. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev, 2010;(1):CD003974. PMID 20091554 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/20091554/
  20. Mendias CL, Awan TM. [Narrative review of 12 approved and unapproved peptides marketed directly to patients.] Sports Med, 2026;56(8):1921–1935. PMID 41966639 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/41966639/
  21. Federal Trade Commission. Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 CFR 255.2 (consumer endorsements). Code of Federal Regulations, current eCFR text; read 21 Nov 2026. www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-25…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Do peptides work?

It depends on the peptide and the use. An approved peptide medicine has been reviewed by a regulator for the uses on its label. For BPC-157, 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical.

How do peptides work?

Many act as messengers: a peptide hormone binds a receptor on the surface of a target cell, and the receptor passes the signal inside. A mechanism seen in cells or animals still has to be tested in people.

Why can’t a photo show that a peptide worked?

A photo pair has no comparison group, and pose, editing, other changes over time and the choice of which photos get posted all affect it. A 2018 review of this kind of comparison names eleven sources of bias.

Are testimonials evidence?

Not scientific evidence. The US Federal Trade Commission’s endorsement guides say: “Consumer endorsements themselves are not competent and reliable scientific evidence.”

Which peptides have been tested in randomised trials in people?

Approved medicines such as semaglutide have: one trial enrolled 1,961 adults. For BPC-157, the only randomised, placebo-controlled data are conference abstracts from 2002 to 2005. Our graded list goes compound by compound.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page